Dear Healthcare Professional,
This website will provide you with a comprehensive overview of the phase III clinical trials COMPETE and COMPOSE for the treatment of neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs). Here, you will find extensive pertinent information about the study designs, inclusion and exclusion criteria, participating clinical centers, the investigational therapy agent, and more.
Your COMPETE and COMPOSE Teams
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
For more information please visit: www.itm.ag